Loading...
•
Dec 31, 2020
Tandem Diabetes Q4 2020 Earnings Report
Announced fourth quarter and full year 2020 financial results and 2021 financial guidance.
Key Takeaways
Tandem Diabetes Care reported a strong fourth quarter with a 55% increase in sales and a 67% increase in worldwide pump shipments. The company's operating margin improved significantly, and they surpassed 200,000 customers worldwide.
Worldwide pump shipments increased 67 percent to 32,685 pumps.
Sales increased 55 percent to $168.1 million.
Adjusted EBITDA remained consistent at 21 percent of sales.
Operating margin improved to 11 percent.
Tandem Diabetes
Tandem Diabetes
Tandem Diabetes Revenue by Geographic Location
Revenue by Geographic Location
United States Revenue
CapyFin.comOutside the United States Revenue
CapyFin.com Forward Guidance
For the year ending December 31, 2021, the Company estimates sales to be in the range of $600 million to $615 million, gross margin to be approximately 55 percent and Adjusted EBITDA to be 14 percent to 15 percent of sales.
Positive Outlook
- Sales are estimated to be in the range of $600 million to $615 million, which represents an annual sales growth of 20 percent to 23 percent compared to 2020
- Includes international sales of approximately $105 million to $110 million
- Gross margin is estimated to be approximately 55 percent
- Adjusted EBITDA is estimated to be 14 percent to 15 percent of sales
- Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $80 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income